Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mechanisms Involved with Tumor Relapse Identified

15.03.2007
Researchers work toward creating a tailored breast cancer vaccine

Researchers at Virginia Commonwealth University's Massey Cancer Center studying the interaction between the immune system and cancer cells have identified interferon gamma as one of the signaling proteins involved with tumor relapse.

The findings may help researchers develop tailored vaccines and other immunotherapeutic strategies to fight a number of cancers. Immunotherapy involves the manipulation of the immune system – by introducing an antibody or lymphocytes, or immunization with a tumor vaccine – to recognize and eradicate tumor cells.

Using a transgenic mouse model of breast cancer, researchers found that interferon gamma, a cytokine or chemical messenger that is produced by cells of the immune system upon activation, plays a role in tumor relapse. In humans, interferon gamma is also produced by white blood cells of the immune system in response to invasion by pathogens or tumors in order to protect the host against infection or cancers. Production of interferon gamma by lymphocytes against tumors is considered a sign of good prognosis; however, recent study findings indicate that this may not be the case. The findings were reported in the March 2007 issue of the European Journal of Immunology, the official journal of the European Federation of Immunological Societies.

"By understanding the molecular mechanisms involved with tumor relapse, we can create tailored vaccines that can induce specific types of immune responses in patients, rather than inducing a broad range of immune responses - some of which may be detrimental or may induce tumor relapse," said lead investigator, Masoud H. Manjili, D.V.M., Ph.D., a member scientist with the Massey Cancer Center.

"Ultimately, we hope to offer a new polypeptide vaccine approach that induces tumor killing without causing HER-2/neu loss. Loss of HER-2/neu is a mechanism that tumors utilize to escape the immune-mediated destruction," he said.

Since 2000, Manjili and his colleagues have been employing animal models of breast cancer to evaluate anti-tumor efficacy of a vaccine formulation they created. This vaccine formulation combines a heat shock protein 110 (HSP110), as an adjuvant, with a tumor antigen HER-2/neu, as a protein target expressed in breast tumors. Adjuvants are agents that are able to modify another agent – basically working as a chemical catalyst.

The work is supported by the National Cancer Institute and the Susan G. Komen Breast Cancer Foundation.

Manjili, who is an assistant professor in the Department of Microbiology and Immunology in the VCU School of Medicine, collaborated with VCU researchers Maciej Kmieciak, Ph.D., with the Department of Microbiology and Immunology, and Catherine I. Dumur, Ph.D., with the Department of Pathology; and Keith L. Knutson, Ph.D., with the Department of Immunology at the Mayo Clinic College of Medicine in Rochester, Minn.

Sathya Achia-Abraham | EurekAlert!
Further information:
http://www.vcu.edu

Further reports about: Cancer Gamma Immunology immune system interferon gamma relapse

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

Construction of practical quantum computers radically simplified

05.12.2016 | Information Technology

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>